Using Ga-68-CXCR4 PET/CT to improve detection of indolent B-cell lymphoma
Ga-68-CXCR4 PET/CT in Detecting, Evaluating Response to Treatment, and Monitoring Risk of Aggressiveness of Indolent B-cell Lymphoma
This study is testing a new type of PET scan to see if it can better detect and monitor slow-growing B-cell lymphoma in patients compared to the current method.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 20 Years to 100 Years |
| Sex | All |
| Sponsor | Koo Foundation Sun Yat-Sen Cancer Center Academic / other |
| Locations | 1 site (Taipei, Beitou) |
| Trial ID | NCT06461182 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of Ga-68-PentixaFor PET/CT imaging in detecting and monitoring indolent B-cell non-Hodgkin lymphoma. It aims to assess treatment responses and the potential for disease aggressiveness, addressing the limitations of the current FDG-PET imaging method, which is less accurate for low-grade lymphomas. Participants will undergo Ga-68-CXCR4 PET/CT scans as part of their clinical evaluation, particularly if they are scheduled for FDG PET scans within a specified timeframe.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with slow-growing B-cell lymphomas who are scheduled for FDG PET scans.
Not a fit: Patients with severe renal impairment, other malignancies, or those unable to undergo the PET scan procedure may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate detection and monitoring of indolent B-cell lymphoma, improving patient management.
How similar studies have performed: While Ga-68-PentixaFor PET has shown promise in various lymphomas, this specific application in indolent B-cell lymphoma is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The pathological diagnosis is slow-growing lymphoma, such as: marginal-zone B-cell lymphoma, Waldenstrom macroglobulinemia lymphocytic lymphoma, CLL/SLL, mantle cell lymphoma. * Have undergone or planned to undergo FDG PET scan for indications including initial staging, therapeutic response evaluation, or follow-up examinations within 3 to 6 months in the clinical observation group. * Able to lie flat for at least 30 minutes. * Signing the subject consent form. * ECOG grade 0-2. * The timing of F-18-FDG usage in this trial follows the "Lymphoma Treatment Principles" of our institution. Exclusion Criteria: * Pregnant woman * Severe renal impairment (eGRF\< 30ml/min) * Known or suspected allergy to radiopharmaceuticals * Concurrent or previous diagnosis of malignancies other than lymphoma * Inability to undergo the necessary PET scan procedure * Refusal or unwillingness to sign the informed consent form * Severe medical conditions (severe disabilities, mental disorders)
Where this trial is running
Taipei, Beitou
- Koo Foundation Sun Yat-Sen Cancer Center — Taipei, Beitou, Taiwan (Recruiting)
Study contacts
- Study coordinator: Yu Yi Huang, MD
- Email: yuyi@kfsyscc.org
- Phone: +886 28970011
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.